VJHemOnc is committed to improving our service to you

COSTEM 2019 | Blinatumomab for R/R Ph+ AML

VJHemOnc is committed to improving our service to you

Giovanni Martinelli

Giovanni Martinelli, MD, University in Bologna, Bologna, Italy, elaborates on his study regarding blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (R/R Ph+ ALL). This interview was recorded at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter